Tissue-specific effects of valsartan on rstn and fiaf gene expression in the ob/ob mouse

Area of Science:

• Endocrinology
• Molecular Biology
• Pharmacology

Background:

• The renin-angiotensin system (RAS) is a novel target in diabetes research.
• Angiotensin receptor blockers (ARBs), like valsartan, may influence adipose tissue function.
• Adipokines, such as resistin (rstn) and fasting-induced adipose factor (fiaf), play roles in metabolic regulation.

Purpose of the Study:

• To investigate the effect of valsartan on rstn and fiaf gene expression in obese and diabetic ob/ob mice.
• To determine if valsartan influences adipokine expression in various tissues, including adipose tissue, pituitary, cerebral cortex, and hypothalamus.

Main Methods:

• Utilized obese and diabetic ob/ob mouse models.
• Quantified mRNA levels of rstn and fiaf in visceral fat, subcutaneous fat, pituitary, cerebral cortex, and hypothalamus.
• Administered valsartan treatment for 2 weeks to assess its impact on gene expression.

Main Results:

• Fiaf gene expression was elevated 2-4 fold in visceral and subcutaneous fat of ob/ob mice compared to lean controls.
• Valsartan treatment normalized fiaf mRNA levels in subcutaneous fat, but not visceral fat, of ob/ob mice.
• Fiaf expression was reduced in the hypothalamus of ob/ob mice, independent of valsartan.
• Rstn expression was significantly reduced in visceral fat of ob/ob mice, but unaffected by valsartan.
• Rstn expression remained unchanged in other examined tissues regardless of valsartan treatment.

Conclusions:

• Valsartan demonstrates tissue-specific effects on adipokine gene expression in obese and diabetic mice.
• The normalization of fiaf in subcutaneous fat suggests a potential therapeutic role for valsartan in modulating adipose tissue dysfunction.
• Further research is warranted to elucidate the precise mechanisms underlying valsartan's influence on adipokines and its implications for diabetes treatment.